Watch CRVS. Know when insiders buy.
One email the day a filing lands. Free.
CRVS
Corvus Pharmaceuticals, Inc.
12.94
−0.39 −2.93%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
39
FLAG · shorts 39
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.1BP/E —DIV YIELD —FCF YIELD -4.15%REV TTM —NET INCOME −$54.1MNET CASH —52W 5.74 – 25.52SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$19.3M | −$18M | — | -0.19 | −$15.4M | $582K | −$16M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$14.9M | −$13.7M | −190.1% | -0.15 | −$10.4M | $91K | −$10.5M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$12.2M | −$12.3M | — | -0.15 | −$9.2M | $25K | −$9.2M | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$10.6M | −$10.2M | — | -0.12 | −$9.6M | $0 | −$9.6M | Nov 4 |
| Q2 2025 · Jun 30 | — | — | — | −$10.3M | −$8M | — | -0.10 | −$5.8M | $113K | −$5.9M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$9.9M | $15.2M | — | -0.13 | −$8.3M | $36K | −$8.3M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$8.1M | −$12.1M | — | -0.16 | −$8.5M | — | — | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$7.3M | −$40.2M | — | -0.60 | −$6.3M | — | — | Nov 4 |
| Q2 2024 · Jun 30 | — | — | — | −$5.9M | −$4.3M | — | -0.07 | −$5.5M | — | — | Nov 4 |
| Q1 2024 · Mar 31 | — | — | — | −$6.3M | −$5.7M | — | -0.12 | −$5.2M | — | — | Nov 4 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.7M | −$6.7M | — | -0.13 | −$5.2M | $0 | −$5.2M | Mar 12 |
| Q3 2023 · Sep 30 | — | — | — | −$5.6M | −$6M | — | -0.12 | −$5.4M | $0 | −$5.4M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$43M | −$15.3M | — | -0.53 | −$32.8M | $174K | −$33M | — | — |
| FY2024 · to Dec 31 | — | — | −$27.5M | −$62.3M | — | -1.02 | −$25.4M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$23.4M | −$27M | — | -0.56 | −$23.9M | $34K | −$24M | — | — |
| FY2022 · to Dec 31 | — | — | −$32.6M | −$41.3M | — | -0.89 | −$27M | $269K | −$27.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$38.6M | −$43.2M | — | -1.03 | −$36.7M | $5K | −$36.7M | — | — |
| FY2020 · to Dec 31 | — | — | −$43.8M | −$6M | — | -0.20 | −$34.8M | $76K | −$34.9M | — | — |
Every number comes from Corvus Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.